menu search

GLUE / Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. Read More
Posted: Oct 24 2023, 11:18
Author Name: Zacks Investment Research
Views: 102084

GLUE News  

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

By Zacks Investment Research
October 24, 2023

Down -56.34% in 4 Weeks, Here's Why You Should You Buy the Dip in Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics (GLUE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combi more_horizontal

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

By Zacks Investment Research
January 25, 2023

How Much Upside is Left in Monte Rosa Therapeutics (GLUE)? Wall Street Analysts Think 226.46%

The mean of analysts' price targets for Monte Rosa Therapeutics (GLUE) points to a 226.5% upside in the stock. While this highly sought-after metric h more_horizontal


Search within

Pages Search Results: